startup
Bristol’s Astral Systems secures €26 million Series A to support medical isotope commercialisation
Source:
eu-startups.com 1 min read
Share
You are reading a summary. The full content is hosted on eu-startups.com.
Astral Systems, a British DeepTech firm pioneering multi-state fusion (MSF) technology, has secured €26 million (£23 million) in Series A funding in order to bring critical medical isotopes to market by early 2027, scaling the production of its modular MSF reactors, and advancing fusion research. This first close investment was led by Mercia Ventures and […] The post Bristol’s Astral Systems secures €26 million Series A to support medical isotope commercialisation appeared first on EU-Startups.
Read the full article on the original website
External link to eu-startups.com
Related Articles
startup
Sources: Uber halts plans to launch food delivery in five of the seven European countries it had targeted for expansion as it pursues a Delivery Hero takeover (Kieran Smith/Financial Times)
1 min read •
startup
India issues a notice to Telegram, asking it to curb the spread of pirated films and other copyrighted content, and seeks an action-taken report within 15 days (Sejal Sharma/Hindustan Times)
1 min read •
startup
Trump's God, guns and anticommunist Fourth of July
2 min read •